Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

RNN - Rexahn Pharmaceuticals Inc.

Previous close
5.24
5.240   100.000%

Share volume: 0
Last Updated: Fri 07 Jun 2019 10:00:00 PM CEST
Biotechnology: -0.86%

PREVIOUS CLOSE
CHG
CHG%
N/A
0.00
0.00%
This ticker is disabled and data are no longer maintained and up to date.
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
30%
Profitability 34%
Dept financing 32%
Liquidity 21%
Performance 29%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
0   0%
1 Month
0   0%
3 Months
0   0%
6 Months
0   0%
1 Year
0   0%
2 Year
0   0%
Key data
Stock price
$5.24
P/E Ratio 
N/A
DAY RANGE
$5.24 - $5.24
EPS 
-$5.16
52 WEEK RANGE
$4.71 - $23.64
52 WEEK CHANGE
-$76.52
MARKET CAP 
21.086 M
YIELD 
N/A
SHARES OUTSTANDING 
4.024 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
N/A
BETA 
0.00
PUBLIC FLOAT 
$3,960,879
AVERAGE 10 VOLUME 
$26,308
AVERAGE 30 VOLUME 
$34,059
Company detail
CEO: Douglas J. Swirsky
Region: US
Website: http://www.rexahn.com
Employees: 10
IPO year: -
Issue type: Common Stock
Market: NYSE American
Industry: Biotechnology
Sector: Health Technology

Rexahn Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in the research and development of oncology therapeutics. Its drug candidates include the following: RX-31171 for pancreatic, bladder, colon, and lung cancer; and RX-5902 for metastatic triple negative breast cancer. The company was founded by Chang Ho Ahn on March 19, 2001 and is headquartered in Rockville, MD.

Recent news